Abstract:High-grade gliomas (HGGs) are the most aggressive primary brain tumors, and molecular characterization is vital for their diagnosis and treatment. Due to their location, tumor sampling is often challenging. Therefore, developing minimally invasive diagnostic methods is urgently needed. Here we report that circulating tumor DNA (ctDNA) from cerebrospinal fluid (CSF) can identify key genomic alterations and track clonal evolution in HGGs. Detection of CSF ctDNA correlates with leptomeningeal disease and overall survival, indicating its potential for integration into clinical decision-making. Our study includes 313 samples from 253 patients with recurrent glioma treated at MSKCC who underwent CSF collection using the MSK-IMPACT targeted sequencing assay. 37% of genomic alterations were detected using our less stringent variant calling criteria and Gaussian Mixture Model to call copy number events. CSF ctDNA positivity was determined by the presence of at least one oncogenic disease-defining alteration or any shared alteration with the tumor. We found 212 CSF ctDNA positive (68%) and 101 CSF ctDNA negative (32%) samples. CSF ctDNA positivity was the highest amongst histone mutant tumors (96%). We noticed 44% of alterations shared between the tumor and the CSF, additionally, we noted considerable tumor evolution particularly within the growth signaling pathways (e.g. PDGFRA). Our cohort demonstrated that patients with positive CSF ctDNA had a significantly shorter overall survival compared to those who were CSF ctDNA negative (4.83 months vs 14.14 months, HR 2.4, p < 0.001). Radiographic findings such as enhancing disease and contact of the tumor with the ventricular space were positively associated with CSF ctDNA positivity. Additionally, CSF ctDNA was associated with positive cytology in 12/12 cases (100%). With our improved pipeline, we hypothesize CSF ctDNA may be used as a prognostic biomarker for survival, but confirmation requires further validation in a prospective study.

Circulating tumor cell is a common property of brain glioma and promotes the monitoring system

Circulating Tumor Cells in Prostate Cancer Diagnosis and Monitoring: An Appraisal of Clinical Potential

Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry.

Circulating Tumor Cells for Glioma

Use of circulating tumor cells and microemboli to predict diagnosis and prognosis in diffuse glioma

Telomerase-positive circulating tumor cells are associated with poor prognosis via a neutrophil-mediated inflammatory immune environment in glioma

Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance

Classifying circulating tumor cells to monitor cancer progression

Circulating Tumor Cells in Gastrointestinal Cancers: Current Status and Future Perspectives

Circulating tumor cells: biology and clinical significance

Circulating tumor cell characterization of lung cancer brain metastases in the cerebrospinal fluid through single‐cell transcriptome analysis

Detection and clinical significance of circulating tumor cells in patients with gastrointestinal stromal tumors

Biom-48. Utility Of Circulating Tumor Dna (Ctdna) From Cerebrospinal Fluid (Csf) For Prognosis Of Patients With Recurrent High-Grade Glioma

Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology – A Pilot Study

Circulating Tumor Cells: Biological Features and Survival Mechanisms

Cytoplasm Protein GFAP Magnetic Beads Construction and Application As Cell Separation Target for Brain Tumors

Clinical applications of circulating tumor cell detection: challenges and strategies

Cerebrospinal Fluid Circulating Tumor DNA Depicts Profiling of Brain Metastasis in NSCLC

Sorting and Identification of Circulating Tumor Cells of Gliomas with EGFR Antibody-Modified Immunomagnetic Microspheres

Dynamic Monitoring of Circulating Tumour Cells to Evaluate Therapeutic Efficacy in Advanced Gastric Cancer

Circulating tumor cells in gastric cancer: developments and clinical applications